Drug intelligence / Profile preview

PSY-01

Development stage: Preclinical
Lead developer: Psy Therapeutics
Modality: Small Molecules

Overview

PSY-01 is a small molecule drug candidate under development by Psy Therapeutics. It is being advanced as a potential best-in-class treatment for Major Depressive Disorder (MDD) and Parkinson's Disease (PD), aiming to offer improved efficacy and safety profiles compared to existing therapies. Psy Therapeutics focuses on addressing significant unmet needs in neuropsychiatric and neurological disorders through its pipeline of small molecule drug candidates, which are designed to be highly brain-penetrant and well-tolerated.

Beyond the preview

Go deeper on PSY-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSY-01.

Explore the full profile